Core Insights - Waterdrop Inc. reported a net operating revenue of RMB 974.9 million for Q3 2025, marking a 38.4% year-over-year increase and a net profit of RMB 158.5 million, up 60.1% from the previous year, maintaining profitability for the fifteenth consecutive quarter [1] Financial Performance - Net operating revenue reached RMB 974.9 million, a 38.4% increase year-over-year [1] - Net profit attributable to ordinary shareholders was RMB 158.5 million, reflecting a 60.1% increase year-over-year [1] - Operating expenses accounted for 39.6% of revenue, down 8.3 percentage points year-over-year [1] Insurance Business - Insurance-related revenue was RMB 869.7 million, up 44.8% year-over-year [1] - Operating profit from the insurance business reached RMB 176.4 million, a 44% increase year-over-year [1] - First-year premiums (FYPs) increased by 32.3% quarter-over-quarter [1] - AI-driven initiatives led to an 82% increase in premiums facilitated by the "AI Medical Insurance Expert" on a quarter-over-quarter basis [1] Medical Crowdfunding - Waterdrop Medical Crowdfunding raised a cumulative RMB 71.2 billion for 3.61 million patients as of September 30, 2025 [1] - Enhanced risk control measures and advanced analytics improved fraud detection and transparency in fund distribution [1] Digital Clinical Trials - The E-Find Platform generated revenues of approximately RMB 31.9 million, a 31.3% year-over-year increase [1] - Cumulatively enrolled 13,282 patients into 1,491 clinical trial programs [1] - Over one thousand patients were enrolled in the third quarter alone [1] Social Responsibility and ESG - Waterdrop released its 2024 ESG report, optimizing its governance structure and enhancing data management capabilities [1] - Collaborated with 119 public charity organizations and launched over 15,500 public welfare projects [1] Future Outlook - The company aims to deepen AI integration and drive innovation across its business ecosystem to fuel sustainable growth [2]

Core Insights - Waterdrop Inc. reported significant profit growth in Q3 2025, with operating profit reaching RMB 113.8 million (US$ 16.0 million), a year-over-year increase of 329.8% [1] - The company experienced rapid revenue expansion, with net operating revenue of RMB 974.9 million (US$ 136.9 million), up 38.4% year-over-year [1] - The insurance-related income surged to RMB 869.7 million (US$ 122.2 million), reflecting a 44.8% increase from the same period in 2024 [1] Financial Highlights - Operating profit for Q3 2025 was RMB 113.8 million (US$ 16.0 million), compared to RMB 26.5 million in Q3 2024 [2] - Net profit attributable to ordinary shareholders was RMB 158.5 million (US$ 22.3 million), a 60.1% increase year-over-year [1] - Adjusted net profit for Q3 2025 was RMB 167.7 million (US$ 23.6 million), up from RMB 126.0 million in Q3 2024 [3] Revenue Breakdown - Insurance segment revenue was RMB 869.7 million (US$ 122.2 million), a 44.8% increase year-over-year [1] - Crowdfunding service fees remained stable at RMB 65.7 million (US$ 9.2 million), nearly unchanged from RMB 65.8 million in Q3 2024 [1] - Digital clinical trial solution income rose to RMB 31.9 million (US$ 4.5 million), marking a 31.3% increase from the previous year [1] Cost and Expense Analysis - Operating costs and expenses increased by 27.1% year-over-year to RMB 861.1 million (US$ 121.0 million) [1] - Sales and marketing expenses rose by 40.3% year-over-year to RMB 243.0 million (US$ 34.1 million) [1] - General and administrative expenses decreased by 23.7% year-over-year to RMB 84.7 million (US$ 11.9 million) [1] Operational Developments - The company enrolled 13,282 patients into 1,491 clinical trial programs through its E-Find Platform as of September 30, 2025 [1] - Waterdrop Medical Crowdfunding facilitated donations totaling RMB 71.2 billion to 3.61 million patients [1] - The company repurchased approximately 58.1 million ADSs from the open market, totaling around US$ 113.4 million as of November 30, 2025 [1]

Core Insights - Waterdrop Inc. reported strong financial results for Q2 2025, with significant revenue and profit growth driven by AI integration in sales and services [2][3][9]. Financial Performance - Net operating revenue for Q2 2025 increased by 23.9% year-over-year to RMB 838.0 million (US$ 117.0 million) from RMB 676.2 million in Q2 2024 [9]. - Operating costs and expenses rose by 18.7% year-over-year to RMB 740.6 million (US$ 103.4 million) [10]. - Net profit attributable to ordinary shareholders reached RMB 140.2 million (US$ 19.6 million), a 58.7% increase year-over-year [11][15]. - Adjusted net profit attributable to ordinary shareholders (non-GAAP) was RMB 151.6 million (US$ 21.2 million), up from RMB 108.7 million in Q2 2024 [16]. Business Segments - The insurance business saw first-year premiums (FYP) grow by 80.2% year-over-year, reaching RMB 3,204.3 million (US$ 447.3 million) [11]. - Insurance-related income increased by 28.7% year-over-year to RMB 738.6 million (US$ 103.1 million) [12]. - Medical crowdfunding services generated RMB 67.4 million (US$ 9.4 million) in service fees, a slight decrease of 2.7% year-over-year [12]. - Digital clinical trial solution income rose by 34.2% year-over-year to RMB 27.7 million (US$ 3.9 million) [12]. Operational Highlights - The "Waterdrop Guardian" AI Application Suite enhanced user experience, with premiums facilitated by the 'AI Medical Insurance Expert' increasing by 155% compared to the previous quarter [4]. - The E-Find Platform expanded its collaboration to 198 pharmaceutical and contract research organizations, enrolling a record 999 patients in Q2 2025, representing a 34.2% year-over-year revenue growth [7]. Shareholder Returns - The board approved a cash dividend of US$ 10.9 million, a 50% increase over the previous dividend [8][20]. - The company has repurchased approximately 55.7 million ADSs for US$ 109.0 million since the launch of its first share repurchase program in 2021 [18]. Future Outlook - The company aims to continue delivering top-line and bottom-line growth in the second half of 2025, emphasizing tech-driven innovation as a core strategy [9].